technology Provide New Insights into Toxicology and Pharmacology -->
By a News Reporter-Staff News Editor at Drug Week -- Research findings on Drugs and Therapies are discussed in a new report. According to news reporting originating in Beijing, People's Republic of China, by NewsRx journalists, research stated, "The safety of rAd5-hTERTC27, a replication defective adenovirus vector carrying hTERTC27 for possible use against hepatocellular carcinoma (HCC) was assessed. In single-dose evaluations, intravenous dose levels of up to 2 x 10(11) VP/kg in rats and 9 x 10(10) VP/kg in monkeys were well tolerated with no abnormal changes in general signs, body weight and food consumption, and no significant differences in biochemical parameters, urinalysis, ECG, and systemic necropsy observations between the rAd5 groups and solvent control group except that slight hematological change was observed."
The news reporters obtained a quote from the research from the Beijing Institute of Biotechnology, "No hemolytic effect using rabbit blood, local perivasculitis following intravenous injection in rabbits or systemic anaphylaxis in guinea pigs following intravenous dosing was seen. No effects on the central nervous system of mice occurred following intravenous dosing with the exception of an increase in sleep duration at the dose of 1.2 x 10(11) VP/kg (p < 0.05) but not at lower doses of 2 x 10(10) and 6 x 10(10) VP/kg in the hypnotic synergism test."
According to the news reporters, the research concluded: "These results demonstrate that administration of rAd5-hTERTC27 was well tolerated in an initial set of safety studies as part of an evaluation to allow human trials for the treatment of HCC."
For more information on this research see: Preclinical safety evaluation of rAd5-hTERTC27 by intravenous injection. Regulatory Toxicology and Pharmacology, 2013;67(1):53-62. Regulatory Toxicology and Pharmacology can be contacted at: Academic Press Inc Elsevier Science, 525 B St, Ste 1900, San Diego, CA 92101-4495, USA. (Elsevier - www.elsevier.com; Regulatory Toxicology and Pharmacology - www.elsevier.com/wps/product/cws_home/622939)
Our news correspondents report that additional information may be obtained by contacting P.J. Yue, Beijing Inst Biotechnol, Lab Tumor & Mol Biol, Beijing, People's Republic of China. Additional authors for this research include L. He, Y. Li, Q.Y. Shen, M. Li, D.Q. Huang, J.J. Huang and Y. Peng (see also Drugs and Therapies).
Keywords for this news article include: Asia, Beijing, Drugs and Therapies, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC